Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

1838 United States sites

1239 India sites

492 United Kingdom sites

365 Canada sites

358 Italy sites

296 Turkey sites

262 Greece sites

201 France site

197 Spain sites

98 South Africa sites

43 Lebanon sites

4 Switzerland sites

3 Oman sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

Locations

719 Brazil sites

500 Turkey sites

377 United States sites

360 Spain sites

284 Italy sites

190 France sites

178 United Kingdom sites

47 Netherlands sites

46 South Africa sites

35 Kenya sites

12 Lebanon sites

Age

12 Years - 55 Years

Phase

Phase 2

LEARN MORE
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Locations

505 United States sites

237 Belgium sites

237 Brazil sites

237 Turkey sites

158 France sites

158 Italy sites

158 Lebanon sites

81 Colombia site

79 Oman sites

79 Germany sites

79 Spain sites

Age

> 6 Months Years

Phase

Phase 4

LEARN MORE
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years.

Locations

1799 United States sites

429 Spain sites

342 Belgium sites

260 United Kingdom sites

258 India sites

257 Germany sites

256 Brazil sites

256 Colombia sites

256 Italy sites

172 Canada sites

172 Lebanon sites

172 Turkey sites

87 Switzerland sites

86 France sites

85 Oman sites

Age

6 Months - 17 Years

Phase

Phase 2

LEARN MORE